Ask AI
ProCE Banner Activity

Expert Highlights From the 2025 World Conference on Lung Cancer

Podcast Episodes

Listen to Dr John Heymach and Dr Solange Peters discuss key data presented at the 2025 World Conference on Lung Cancer regarding frontline maintenance for extensive-stage small-cell lung cancer and targeted treatments for non-small-cell lung cancer and how they may change the treatment paradigm.

Released: December 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for oncologists, nurses, physician associates, pharmacists, and other healthcare professionals caring for patients with lung cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recently presented data, as appropriate and guided by expert recommendations, into the treatment of patients with lung cancers to improve outcomes and quality of life

  • Distinguish subpopulations of patients with lung cancers most likely to benefit from specific treatment based on prognostic or predictive markers

  • Interpret new data on novel agents and therapeutic strategies for patients with lung cancers to aid integration into practice

Disclosure

Primary Author

John Heymach, MD, PhD: advisor: 23andMe, AstraZeneca, Bayer, BioNTech AG, Boehringer Ingelheim, Bristol Myers Squibb, Curios Science, DAVA Oncology, EMD Serono, IDEOlogy Health, Intellisphere, InxMed (Hong Kong) Limited, Janssen, Jazz, Lilly, Mirati, ModeX, OncoHost, Ottimo, Pfizer, Regeneron, Remunity Therapeutics, Synthekine, Takeda; researcher: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Mirati, Takeda; owner: Tenaci-T Therapeutics; licensing/royalties: Spectrum.

Solange Peters, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Lilly, Merck Sharp & Dohme, Merck Serono, Novartis, Novocure, Nuvation Bio, Nuvalent, Nykode, PharmaMar, Promontory, Pfizer, Qlucore, Regeneron, Roche/Genetech, Sanofi, Takeda, Zymeworks; researcher (paid to institution): Amgen, Arcus, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, iTeos, Lilly, Merck Sharp & Dohme, Mirati, Pharma Mar, Pfizer, Promontory, Roche/Genentech.